Pexerelgon vs R2R01
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Relaxin receptor (RXFP1) / relaxin · full Heart Failure pipeline
Pexerelgon
Developed by AstraZeneca
NCT06299826 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, with 375 participants across three AZD5462 dose groups and a placebo group. Its primary endpoint was a surrogate echocardiographic measure, and no primary-outcome results or statistical comparison are currently available.
No aligned efficacy figure on record for this race.
R2R01
Developed by River 2 Renal
NCT06264310 · Phase 2 · completed
The study randomly assigned participants to R2R01 or placebo and used blinded treatment, but only 33 participants were enrolled across four groups. Its primary endpoint was safety and tolerability, and no primary-endpoint results or statistical comparison are posted, so the trial provides limited evidence at this time. Its registered primary outcome on ClinicalTrials.gov is "Number and rate of patients with one or more TEAEs (treatment emergent AE's) and/or serious TEAEs as assessed by CTCAE v5.0." (with 1 other safety or dose-finding measure). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
No aligned efficacy figure on record for this race.
Results for Heart Failure
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Pexerelgon | R2R01 |
|---|---|---|
| CV death or HF hospitalisation | —Not reported | —Not reported |
| HF hospitalisation | —Not reported | —Not reported |
| CV death | —Not reported | —Not reported |
| KCCQ clinical summary, change | —Not reported | —Not reported |
CV death or HF hospitalisation
- Pexerelgon
- —Not reported
- R2R01
- —Not reported
HF hospitalisation
- Pexerelgon
- —Not reported
- R2R01
- —Not reported
CV death
- Pexerelgon
- —Not reported
- R2R01
- —Not reported
KCCQ clinical summary, change
- Pexerelgon
- —Not reported
- R2R01
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Pexerelgon: no structured comparison results are available for Heart Failure.
R2R01: no structured comparison results are available for Heart Failure.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Pexerelgon's landscape · R2R01's landscape